Sagility shares fall 4% despite 22% revenue growth in Q2: Should you buy, sell or hold?
Executive Brief • Key Highlights
Fast factual intelligence distilled for busy investors, executives, and answer bots:
- ✓Sagility India shares fell nearly 4% on October 23 despite the company reporting 22% revenue growth in Q2.
- ✓While revenue and profit rose, investors reacted to market pressures.
- ✓Nomura kept a neutral rating, but Motilal Oswal said to buy the stock.
Story at a Glance
- Category
- MARKET
- Reported By
- MoneyControl
- Reading Speed
- 3 Minute(s)
- Market Focus
- India Economy
Shares of Sagility India fell nearly 4% on October 23, a day after the healthcare technology services provider reported robust results for the September quarter, with revenue and EBITDA growing over 22% year-on-year. Sagility stocks were trading at Rs 43.59 on the NSE, down 3.97%, at 1:32 pm. The company reported a 22.5% year-on-year increase in Q2FY27 revenue to Rs 2,032.1 crore, while EBITDA rose 23.4% to Rs 512.3 crore. Its adjusted EBITDA margin expanded to 26.3%, prompting the company to raise its FY27 adjusted EBITDA margin guidance to 25-26% from 24-25% earlier.
Net profit increased 13.1% year-on-year to Rs 284 crore. Nomura retains 'Neutral', raises target price to Rs 56 Nomura has retained its 'Neutral' rating on Sagility India while raising its target price to Rs 56 from Rs 53 after factoring in the header should have buy sell or hldQ2FY27 results.
Unlock the Full Story with ArthNow Premium
To continue reading this complete financial story and in-depth market context, upgrade to ArthNow Premium. Enjoy unlimited access across Web and Mobile.
MoneyControl
Read the full, original unfiltered story directly on the publisher's portal.